Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Bullón Vela MV, Abete I, Zulet MDLÁ, Tur JA, Pintó X, Corbella E, Martínez González MÁ, Corella D, Macías González M, Tinahones F, Fitó M, Estruch R, Ros E, Salas Salvadó J, Daimiel L, Martínez JA. Risk factors differentially associated with non-alcoholic fatty liver disease in males and females with metabolic syndrome. Rev Esp Enferm Dig 2021;112:94-100. [PMID: 31880161 DOI: 10.17235/reed.2019.6031/2018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]

For:	Bullón Vela MV, Abete I, Zulet MDLÁ, Tur JA, Pintó X, Corbella E, Martínez González MÁ, Corella D, Macías González M, Tinahones F, Fitó M, Estruch R, Ros E, Salas Salvadó J, Daimiel L, Martínez JA. Risk factors differentially associated with non-alcoholic fatty liver disease in males and females with metabolic syndrome. Rev Esp Enferm Dig 2021;112:94-100. [PMID: 31880161 DOI: 10.17235/reed.2019.6031/2018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]

Number

Cited by Other Article(s)

Huang R, Fan JG, Shi JP, Mao YM, Wang BY, Zhao JM, Lu LG, Zhong BH, Zou ZS, Xu YQ, Ye YN, Liu L, Lin LJ, Rao H, Wei L. Stages of psychological change among patients with non-alcoholic fatty liver disease in China: a national cross-sectional study. BMJ Open 2023;13:e062131. [PMID: 37339833 DOI: 10.1136/bmjopen-2022-062131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/22/2023] Open

Abstract

OBJECTIVES

Non-alcoholic fatty liver disease (NAFLD) is becoming the leading cause of chronic liver disease worldwide. However, treatment of NAFLD is potentially influenced by psychological conditions. Using the simplified version of the University of Rhode Island Change Assessment (URICA-SV) scale, this study aimed to evaluate the stage of psychological change as a prerequisite to refining implementation strategies for psychological change.

DESIGN

A multicentre cross-sectional survey.

SETTING

Ninety hospitals in China.

PARTICIPANTS

5181 patients with NAFLD were included in this study.

OUTCOME MEASURES

All patients completed the URICA-SV questionnaire and were assigned to one of the three stages of change (precontemplation, contemplation or action) according to their readiness scores. A stepwise multivariate logistic regression analysis was used to identify independent factors associated with the stage of psychological change.

RESULTS

A total of 4832 (93.3%) patients were included in the precontemplation stage and only 349 (6.7%) considered making a change or preparing to make one. There were significant differences in gender (Cohen's d=0.039, p=0.005), age (Cohen's d=-0.327, p<0.001), waist circumference (Cohen's d=0.143, p=0.003), alanine transaminase (Cohen's d=0.347, p=0.001), triglyceride (Cohen's d=0.351, p=0.002), body mass index (BMI; Cohen's d=0.056, p<0.001), proportion of hyperlipidaemia (Cohen's d=0.068, p<0.001) and cardiovascular disease (Cohen's d=0.032, p=0.029), therapeutic regimen (Cohen's d=0.136, p<0.001), and Chronic Liver Disease Questionnaire-Non-Alcoholic Fatty Liver Disease overall score (Cohen's d=-0.420, p<0.001) between patients with NAFLD in the precontemplation stage and those in the contemplation/action stage. Logistic regression identified BMI (HR 0.659, 95% CI 0.469 to 0.928, p=0.017), cardiovascular disease (HR 2.161, 95% CI 1.089 to 4.287, p=0.027) and triglyceride (HR 0.751, 95% CI 0.591 to 0.955, p=0.020) as independent factors predicting psychological change.

CONCLUSIONS

The results demonstrated that very few patients with NAFLD presented psychological condition in the stage of action. Psychological condition was found to be significantly related to BMI, cardiovascular disease and triglyceride factors. Integrated diversity considerations for evaluating psychological change are necessary.

Collapse

Affiliation(s)

Rui Huang Peking University People's Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China
Jian-Gao Fan Department of Hepatology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
Jun-Ping Shi Department of Hepatology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China
Yi-Min Mao Department of Digestive, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
Bing-Yuan Wang Department of Digestive, The First Hospital of China Medical University, Shenyang, China
Jing-Min Zhao Department of Pathology, The Fifth Medical Center of PLA General Hospital, Beijing, China
Lun Gen Lu Department of Hepatology, The First People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
Bi-Hui Zhong Department of Digestive, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, China
Zheng-Sheng Zou Department of Pathology, The Fifth Medical Center of PLA General Hospital, Beijing, China
You-Qing Xu Department of Digestive, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Yi-Nong Ye Department of Infectious Disease, The First Hospital of Fushan, Fushan, China
Longgen Liu Department of Hepatology, Third People's Hospital of Changzhou, Changzhou, China
Lian-Jie Lin Department of Digestive, Shengjing Hospital of China Medical University, Shenyang, China
Huiying Rao Peking University People's Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China
Lai Wei Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China

Collapse

Funuyet-Salas J, Martín-Rodríguez A, Pérez-San-Gregorio MÁ, Romero-Gómez M. Influence of Psychological Biomarkers on Therapeutic Adherence by Patients with Non-Alcoholic Fatty Liver Disease: A Moderated Mediation Model. J Clin Med 2021;10:2208. [PMID: 34065216 PMCID: PMC8161151 DOI: 10.3390/jcm10102208] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2021] [Revised: 05/17/2021] [Accepted: 05/18/2021] [Indexed: 01/14/2023] Open

Bullón-Vela V, Abete I, Zulet MA, Xu Y, Martínez-González MA, Sayón-Orea C, Ruiz-Canela M, Toledo E, Sánchez VM, Estruch R, Lamuela-Raventós RM, Almanza-Aguilera E, Fitó M, Salas-Salvadó J, Díaz-López A, Tinahones FJ, Tur JA, Romaguera D, Konieczna J, Pintó X, Daimiel L, Rodriguez-Mateos A, Alfredo Martínez J. Urinary Resveratrol Metabolites Output: Differential Associations with Cardiometabolic Markers and Liver Enzymes in House-Dwelling Subjects Featuring Metabolic Syndrome. Molecules 2020;25:molecules25184340. [PMID: 32971870 PMCID: PMC7570830 DOI: 10.3390/molecules25184340] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2020] [Revised: 09/16/2020] [Accepted: 09/18/2020] [Indexed: 02/06/2023] Open

Abstract

Metabolic syndrome (MetS) components are strongly associated with increased risk of non-alcoholic fatty liver disease (NAFLD) development. Several studies have supported that resveratrol is associated with anti-inflammatory and antioxidant effects on health status. The main objective of this study was to assess the putative associations between some urinary resveratrol phase II metabolites, cardiometabolic, and liver markers in individuals diagnosed with MetS. In this cross-sectional study, 266 participants from PREDIMED Plus study (PREvención con DIeta MEDiterránea) were divided into tertiles of total urinary resveratrol phase II metabolites (sum of five resveratrol conjugation metabolites). Urinary resveratrol metabolites were analyzed by ultra- performance liquid chromatography coupled to triple quadrupole mass spectrometry (UPLC-Q-q-Q MS), followed by micro-solid phase extraction (µ-SPE) method. Liver function markers were assessed using serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT). Moreover, lipid profile was measured by triglycerides, very-low-density lipoprotein cholesterol (VLDL-c), and total cholesterol/high-density lipoprotein ratio (total cholesterol/HDL). Linear regression adjusted models showed that participants with higher total urine resveratrol concentrations exhibited improved lipid and liver markers compared to the lowest tertile. For lipid determinations: log triglycerides (β_T3= −0.15, 95% CI; −0.28, −0.02, p-trend = 0.030), VLDL-c, (β_T3= −4.21, 95% CI; −7.97, −0.46, p-trend = 0.039), total cholesterol/HDL ratio Moreover, (β_T3= −0.35, 95% CI; −0.66, −0.03, p-trend = 0.241). For liver enzymes: log AST (β_T3= −0.12, 95% CI; −0.22, −0.02, p-trend = 0.011, and log GGT (β_T3= −0.24, 95% CI; −0.42, −0.06, p-trend = 0.002). However, there is no difference found on glucose variables between groups. To investigate the risk of elevated serum liver markers, flexible regression models indicated that total urine resveratrol metabolites were associated with a lower risk of higher ALT (169.2 to 1314.3 nmol/g creatinine), AST (599.9 to 893.8 nmol/g creatinine), and GGT levels (169.2 to 893.8 nmol/g creatinine). These results suggested that higher urinary concentrations of some resveratrol metabolites might be associated with better lipid profile and hepatic serum enzymes. Moreover, urinary resveratrol excreted showed a reduced odds ratio for higher liver enzymes, which are linked to NAFLD.

Collapse

Affiliation(s)

Vanessa Bullón-Vela Department of Nutrition, Food Science and Physiology, Center for Nutrition Research, University of Navarra, 31008 Pamplona, Spain; (V.B.-V.); (M.A.Z.); (J.A.M.)
Itziar Abete Department of Nutrition, Food Science and Physiology, Center for Nutrition Research, University of Navarra, 31008 Pamplona, Spain; (V.B.-V.); (M.A.Z.); (J.A.M.) Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; (M.A.M.-G.); (C.S.-O.); (M.R.-C.); (E.T.); (R.E.); (R.M.L.-R.); (M.F.); (J.S.-S.); (A.D.-L.); (F.J.T.); (J.A.T.); (D.R.); (J.K.); (X.P.) Correspondence: ; Tel.: +34-94-842-5600 (ext. 806357)
Maria Angeles Zulet Department of Nutrition, Food Science and Physiology, Center for Nutrition Research, University of Navarra, 31008 Pamplona, Spain; (V.B.-V.); (M.A.Z.); (J.A.M.) Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; (M.A.M.-G.); (C.S.-O.); (M.R.-C.); (E.T.); (R.E.); (R.M.L.-R.); (M.F.); (J.S.-S.); (A.D.-L.); (F.J.T.); (J.A.T.); (D.R.); (J.K.); (X.P.)
Yifan Xu Department of Nutritional Sciences, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King’s College London, London SE1 9NH, UK; (Y.X.); (A.R.-M.)
Miguel A. Martínez-González Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; (M.A.M.-G.); (C.S.-O.); (M.R.-C.); (E.T.); (R.E.); (R.M.L.-R.); (M.F.); (J.S.-S.); (A.D.-L.); (F.J.T.); (J.A.T.); (D.R.); (J.K.); (X.P.) Department of Preventive Medicine and Public Health, University of Navarra, 31008 Pamplona, Spain
Carmen Sayón-Orea Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; (M.A.M.-G.); (C.S.-O.); (M.R.-C.); (E.T.); (R.E.); (R.M.L.-R.); (M.F.); (J.S.-S.); (A.D.-L.); (F.J.T.); (J.A.T.); (D.R.); (J.K.); (X.P.) Department of Preventive Medicine and Public Health, University of Navarra, 31008 Pamplona, Spain
Miguel Ruiz-Canela Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; (M.A.M.-G.); (C.S.-O.); (M.R.-C.); (E.T.); (R.E.); (R.M.L.-R.); (M.F.); (J.S.-S.); (A.D.-L.); (F.J.T.); (J.A.T.); (D.R.); (J.K.); (X.P.) Department of Preventive Medicine and Public Health, University of Navarra, 31008 Pamplona, Spain
Estefanía Toledo Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; (M.A.M.-G.); (C.S.-O.); (M.R.-C.); (E.T.); (R.E.); (R.M.L.-R.); (M.F.); (J.S.-S.); (A.D.-L.); (F.J.T.); (J.A.T.); (D.R.); (J.K.); (X.P.) Department of Preventive Medicine and Public Health, University of Navarra, 31008 Pamplona, Spain
Vicente Martín Sánchez Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; Institute of Biomedicine (IBIOMED), University of León, 24071 León, Spain
Ramon Estruch Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; (M.A.M.-G.); (C.S.-O.); (M.R.-C.); (E.T.); (R.E.); (R.M.L.-R.); (M.F.); (J.S.-S.); (A.D.-L.); (F.J.T.); (J.A.T.); (D.R.); (J.K.); (X.P.) Department of Internal Medicine, IDIBAPS, Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain
Rosa María Lamuela-Raventós Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; (M.A.M.-G.); (C.S.-O.); (M.R.-C.); (E.T.); (R.E.); (R.M.L.-R.); (M.F.); (J.S.-S.); (A.D.-L.); (F.J.T.); (J.A.T.); (D.R.); (J.K.); (X.P.) Department of Nutrition, Food Sciences and Gastronomy, XaRTA, INSA-UB, School of Pharmacy and Food Sciences, Nutrition and Food Safety Research Institute, University of Barcelona, 08028 Barcelona, Spain
Enrique Almanza-Aguilera Cardiovascular Risk and Nutrition Research Group (CARIN), Hospital del Mar Research Institute (IMIM), 08007 Barcelona, Spain; CIBER Fragilidad y Envejecimiento Saludable (CIBERFES), Institute of Health Carlos III, 28029 Madrid, Spain Institute of Nutrition and Food Safety (INSA-UB), University of Barcelona, Santa Coloma de Gramenet, 08921 Barcelona, Spain
Montserrat Fitó Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; (M.A.M.-G.); (C.S.-O.); (M.R.-C.); (E.T.); (R.E.); (R.M.L.-R.); (M.F.); (J.S.-S.); (A.D.-L.); (F.J.T.); (J.A.T.); (D.R.); (J.K.); (X.P.) Cardiovascular Risk and Nutrition Research Group (CARIN), Hospital del Mar Research Institute (IMIM), 08007 Barcelona, Spain;
Jordi Salas-Salvadó Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; (M.A.M.-G.); (C.S.-O.); (M.R.-C.); (E.T.); (R.E.); (R.M.L.-R.); (M.F.); (J.S.-S.); (A.D.-L.); (F.J.T.); (J.A.T.); (D.R.); (J.K.); (X.P.) Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, Unitat de Nutrició Humana, 43201 Reus, Spain Institut d’Investigació Pere Virgili (IISPV), Hospital Universitari Sant Joan de Reus, 43204 Reus, Spain
Andrés Díaz-López Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; (M.A.M.-G.); (C.S.-O.); (M.R.-C.); (E.T.); (R.E.); (R.M.L.-R.); (M.F.); (J.S.-S.); (A.D.-L.); (F.J.T.); (J.A.T.); (D.R.); (J.K.); (X.P.) Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, Unitat de Nutrició Humana, 43201 Reus, Spain Institut d’Investigació Pere Virgili (IISPV), Hospital Universitari Sant Joan de Reus, 43204 Reus, Spain
Francisco J. Tinahones Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; (M.A.M.-G.); (C.S.-O.); (M.R.-C.); (E.T.); (R.E.); (R.M.L.-R.); (M.F.); (J.S.-S.); (A.D.-L.); (F.J.T.); (J.A.T.); (D.R.); (J.K.); (X.P.) Department of Endocrinology, Instituto de Investigación Biomédica de Málaga-IBIMA, University of Málaga, Virgen de la Victoria Hospital, 29010 Málaga, Spain
Josep A. Tur Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; (M.A.M.-G.); (C.S.-O.); (M.R.-C.); (E.T.); (R.E.); (R.M.L.-R.); (M.F.); (J.S.-S.); (A.D.-L.); (F.J.T.); (J.A.T.); (D.R.); (J.K.); (X.P.) Research Group on Community Nutrition & Oxidative Stress, University of Balearic Islands, 07122 Palma de Mallorca, Spain
Dora Romaguera Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; (M.A.M.-G.); (C.S.-O.); (M.R.-C.); (E.T.); (R.E.); (R.M.L.-R.); (M.F.); (J.S.-S.); (A.D.-L.); (F.J.T.); (J.A.T.); (D.R.); (J.K.); (X.P.) Research Group on Nutritional Epidemiology & Cardiovascular Physiopathology (NUTRECOR), Health Research Institute of the Balearic Islands (IdISBa), University Hospital Son Espases (HUSE), 07120 Palma de Mallorca, Spain
Jadwiga Konieczna Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; (M.A.M.-G.); (C.S.-O.); (M.R.-C.); (E.T.); (R.E.); (R.M.L.-R.); (M.F.); (J.S.-S.); (A.D.-L.); (F.J.T.); (J.A.T.); (D.R.); (J.K.); (X.P.) Research Group on Nutritional Epidemiology & Cardiovascular Physiopathology (NUTRECOR), Health Research Institute of the Balearic Islands (IdISBa), University Hospital Son Espases (HUSE), 07120 Palma de Mallorca, Spain
Xavier Pintó Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; (M.A.M.-G.); (C.S.-O.); (M.R.-C.); (E.T.); (R.E.); (R.M.L.-R.); (M.F.); (J.S.-S.); (A.D.-L.); (F.J.T.); (J.A.T.); (D.R.); (J.K.); (X.P.) Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, 08908 Barcelona, Spain
Lidia Daimiel Precision Nutrition Program, IMDEA Food, CEI UAM + CSIC, 28049 Madrid, Spain;
Ana Rodriguez-Mateos Department of Nutritional Sciences, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King’s College London, London SE1 9NH, UK; (Y.X.); (A.R.-M.)
José Alfredo Martínez Department of Nutrition, Food Science and Physiology, Center for Nutrition Research, University of Navarra, 31008 Pamplona, Spain; (V.B.-V.); (M.A.Z.); (J.A.M.) Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain; (M.A.M.-G.); (C.S.-O.); (M.R.-C.); (E.T.); (R.E.); (R.M.L.-R.); (M.F.); (J.S.-S.); (A.D.-L.); (F.J.T.); (J.A.T.); (D.R.); (J.K.); (X.P.) Precision Nutrition Program, IMDEA Food, CEI UAM + CSIC, 28049 Madrid, Spain;

Collapse